Broken PBS system behind failure to list Mounjaro for type 2 diabetics, according to Medicines Australia
ABC News Australia
Overall Assessment
The article presents a well-sourced, context-rich account of the Mounjaro PBS listing failure, emphasizing systemic delays and patient impact. It fairly represents industry, patient, and government perspectives, though slightly favors emotional and critical narratives. The editorial stance leans toward reform urgency but remains grounded in evidence.
"Under one type of agreement, if the drug is prescribed to more people than anticipated, the pharmaceutical company"
Cherry Picking
Headline & Lead 85/100
The article reports on the failure to list Mounjaro on the PBS, attributing systemic issues to delays and high costs, with input from industry, government, and patient perspectives. It includes personal impact, policy context, and economic considerations without overt bias. The framing emphasizes structural shortcomings but remains grounded in sourced claims and real-world consequences.
✓ Balanced Reporting: The headline accurately reflects the central claim of the article — that the failure to list Mounjaro on the PBS is attributed to systemic issues, as stated by Medicines Australia. It avoids hyperbole and clearly identifies the source of the claim.
"Broken PBS system behind failure to list Mounjaro for type 2 diabetics, according to Medicines Australia"
✓ Proper Attribution: The headline attributes the assertion to a named entity (Medicines Australia), which allows readers to assess potential bias and grounds the claim in a specific source rather than presenting it as objective fact.
"according to Medicines Australia"
Language & Tone 80/100
The tone is largely neutral but leans slightly toward patient and industry perspectives through emotive personal testimony and repeated emphasis on systemic failure. However, it acknowledges government constraints and pricing rationale. The use of attributed quotes helps maintain objectivity despite loaded terms.
✕ Loaded Language: The term 'broken' is used in both the headline and body to describe the PBS system. While attributed to stakeholders, its placement risks normalizing a negative characterization without sufficient counterbalance.
"broken" process behind subsidising medicines"
✕ Appeal To Emotion: The inclusion of a patient story involving financial hardship and rationing evokes empathy, which is relevant but risks tilting the tone toward emotional persuasion if not carefully balanced with systemic analysis.
"I'm doing without other things to afford the Mounjaro … I can't do anything other than buy the Mounjaro."
✓ Balanced Reporting: The article includes the government's rationale for pricing constraints — protecting taxpayers — which provides a counterweight to pharmaceutical industry complaints.
"the government negotiates with the pharmaceutical company to strike a commercial agreement that aims to protect taxpayers"
Balance 90/100
The article draws from a diverse range of credible sources — industry leaders, patients, and experts — with clear attribution throughout. This strengthens reliability and avoids anonymous or vague sourcing.
✓ Comprehensive Sourcing: The article includes perspectives from the pharmaceutical industry (Medicines Australia, Eli Lilly), a patient (Ingrid Baas-Becking), and an expert (health economist), ensuring multiple stakeholder voices are represented.
✓ Proper Attribution: Claims are consistently attributed to specific actors, such as 'Ms de Somer said' or 'the company estimated', preventing the presentation of opinion as fact.
"Ms de Somer said the latest stalemate over Mounjaro highlighted the need for more urgent action."
Completeness 95/100
The article delivers strong contextual depth, explaining the PBS process, reform efforts, and economic trade-offs. A minor flaw is the abrupt cutoff in the economist’s explanation, which may leave a gap in understanding of cost-mitigation mechanisms.
✓ Comprehensive Sourcing: The article provides background on the PBS listing process, including median approval time (22 months), recent reform efforts (2024 HTA review), and the role of PBAC, giving readers essential policy context.
"a median time of 22 months for a new medicine to land on the scheme once it is approved by the regulator."
✓ Balanced Reporting: It explains not only patient and industry frustrations but also the government's interest in cost containment, presenting the trade-offs inherent in public drug funding.
"protect taxpayers by mitigating risks, like uncertainty around the overall cost to the PBS."
✕ Cherry Picking: The article cuts off mid-sentence in the final quoted section about pharmaceutical agreements, potentially omitting key context about risk-sharing models. This may leave readers with an incomplete understanding of negotiation dynamics.
"Under one type of agreement, if the drug is prescribed to more people than anticipated, the pharmaceutical company"
Medical innovation (e.g., Mounjaro) framed as highly beneficial and life-changing
[balanced_reporting] and [comprehensive_sourcing]: Patient testimony emphasizes dramatic health improvements from Mounjaro, positioning innovation as positive and transformative where access is granted.
"I'm losing weight for the first time in my life and I'm using about 50 per cent less insulin."
PBS system portrayed as failing due to delays and inefficiency
[loaded_language] and [balanced_reporting]: The repeated use of 'broken' to describe the system, attributed to stakeholders but emphasized in headline and body, strongly frames the PBS as dysfunctional. Context on 22-month delays and reform stagnation reinforces failure narrative.
"broken" process behind subsidising medicines"
Patients portrayed as financially endangered by high drug costs
[appeal_to_emotion] and [comprehensive_sourcing]: Personal testimony highlights extreme financial strain, framing affordability as a safety issue for vulnerable populations like pensioners.
"I'm doing without other things to afford the Mounjaro … I can't do anything other than buy the Mounjaro."
Government portrayed as slow and ineffective in responding to healthcare needs
[balanced_reporting] and [cherry_picking]: While government cost concerns are noted, the emphasis on stalled reform and urgent calls to act frame it as lagging despite recognized problems.
"The government has recognised that there's an issue. Stakeholders, patients, patient groups, and their families and communities have recognised there's a problem here," she said. "It's now a time to act, and we're ready and waiting.""
The article presents a well-sourced, context-rich account of the Mounjaro PBS listing failure, emphasizing systemic delays and patient impact. It fairly represents industry, patient, and government perspectives, though slightly favors emotional and critical narratives. The editorial stance leans toward reform urgency but remains grounded in evidence.
The diabetes medication Mounjaro will not be subsidised under the PBS after manufacturer Eli Lilly withdrew from negotiations, citing insufficient pricing offers. The decision follows a PBAC recommendation for listing and reflects ongoing tensions between pharmaceutical companies and Australia's drug funding system. Patients currently pay full cost, with access challenges highlighted among those on lower incomes.
ABC News Australia — Lifestyle - Health
Based on the last 60 days of articles
ABC News Australia
No related content